Intellia Therapeutics (LTS:0JBU) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JBU Intellia Therapeutics Inc LTS:0JBU
69 GF Score
Price $11.95
GF Value $14.27
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Intellia Therapeutics  (LTS:0JBU) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Intellia Therapeutics Cyclically Adjusted PB Ratio Related Terms


Intellia Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted PB Ratio Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.29 0.97

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.89 0.97 1.34 0.00

LTS:0JBU vs SEPN, AVBP, VIR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted PB Ratio falls into.


LTS:0JBU
69GF Score
Intellia Therapeutics Inc LTS:0JBU
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Intellia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Intellia Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.452/333.9520*333.9520
=5.452

Current CPI (Jun. 2026) = 333.9520.

Intellia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.060 241.428 8.382
201612 5.826 241.432 8.059
201703 5.548 243.801 7.599
201706 5.201 244.955 7.091
201709 4.873 246.819 6.593
201712 7.092 246.524 9.607
201803 6.857 249.554 9.176
201806 6.468 251.989 8.572
201809 6.070 252.439 8.030
201812 6.379 251.233 8.479
201903 5.812 254.202 7.635
201906 5.802 256.143 7.564
201909 5.640 256.759 7.336
201912 5.376 256.974 6.986
202003 4.896 258.115 6.334
202006 5.987 257.797 7.756
202009 5.607 260.280 7.194
202012 7.958 260.474 10.203
202103 8.041 264.877 10.138
202106 7.241 271.696 8.900
202109 14.892 274.310 18.130
202112 13.966 278.802 16.729
202203 12.612 287.504 14.650
202206 11.586 296.311 13.058
202209 10.771 296.808 12.119
202212 14.185 296.797 15.961
202303 13.518 301.836 14.956
202306 12.506 305.109 13.688
202309 11.644 307.789 12.634
202312 11.293 306.746 12.295
202403 10.756 312.332 11.501
202406 9.880 314.175 10.502
202409 9.456 315.301 10.015
202412 8.546 315.605 9.043
202503 7.533 319.799 7.866
202506 6.791 322.561 7.031
202509 6.464 324.800 6.646
202512 5.772 324.054 5.948
202603 5.155 330.213 5.213
202606 5.452 333.952 5.452

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Intellia Therapeutics (LTS:0JBU) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $11.95 is trading 16.3% below its estimated GF Value™ of $14.27. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for LTS:0JBU:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $14.27 vs. price of $11.95 (16.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the LTS:0JBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges NTLA:USA38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
69GF Score

Get the complete analysis for LTS:0JBU

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.95
Price
$14.27
GF Value